Clinical trials
Phase 2 clinical trials
Below are recruiting phase 2 clinical trials, each written for real people, not researchers. We’re tracking 292 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06830629RecruitingPhase 2
MZE829 for APOL1 kidney disease
This trial tests an experimental drug called MZE829 for people with kidney disease linked to the APOL1 gene. It aims to see if the drug can help protect kidney function.
Decatur, AlabamaAges 18–68 - NCT06710288RecruitingPhase 2
Immune cell therapy plus chemo for platinum-resistant ovarian cancer
This trial tests a new combination therapy for advanced ovarian cancer that has stopped responding to platinum-based chemo. You will receive your own immune cells (M-CENK) boosted with an immune stimulator (N-803) plus chemotherapy (gemcitabine) to see if this helps fight the cancer.
El Segundo, CaliforniaAges 18–85 - NCT06023758RecruitingPhase 2
Study of two drugs with or without chemo for HER2-positive stomach cancer
This study tests two new immunotherapy drugs (KN026 and KN046) with or without chemotherapy (XELOX) for people with a specific type of advanced stomach cancer that makes too much HER2 protein. The goal is to see if this combination can shrink tumors or slow the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT07101497RecruitingPhase 2
BN104 as maintenance therapy after stem cell transplant for leukemia
This trial tests a new drug called BN104 to help keep leukemia from coming back after a stem cell transplant. It's for people with certain types of acute leukemia that have specific gene changes.
Suzhou, JiangsuAges 12 years+ - NCT06990269RecruitingPhase 2
Study of ADX-038 for geographic atrophy in dry AMD
This trial tests an investigational drug (ADX-038) for people with geographic atrophy, a form of advanced dry age-related macular degeneration. The drug is given as an injection into the eye, and the study checks if it can slow down the growth of GA spots.
Gilbert, ArizonaAges 60 years+ - NCT05632861RecruitingPhase 2
Trial drug for biopsy-proven nonalcoholic steatohepatitis
This Phase 2 trial studies HuHuangLianzonggan Capsule to treat nonalcoholic steatohepatitis (NASH), a liver inflammation caused by fat buildup. You may be eligible if you have confirmed NASH on a recent liver biopsy and meet specific liver fat, lab, and health-condition limits.
Hefei, AnhuiAges 18–75 - NCT07316010RecruitingPhase 2
Liso-cel for lymphoma with minimal residual disease after first treatment
This trial tests a type of CAR T-cell therapy (called liso-cel) for people with large B-cell lymphoma who still have tiny traces of cancer after their first treatment. The goal is to see if liso-cel can get rid of those remaining cancer cells and prevent the cancer from coming back.
Houston, TexasAges 18 years+ - NCT07459166RecruitingPhase 2
Testing a new drug for fentanyl overdose
This study tests a new drug, CS-1103, to see if it can safely help reverse the effects of fentanyl (a strong opioid) even after a naloxone block. Healthy volunteers who have used opioids before will be given fentanyl and then the study drug, while researchers monitor safety and how the drug works.
Glendale, CaliforniaAges 18–55 - NCT07326085Recruiting
Pilot test of MiDiálisis app for home dialysis patients
This study tests a mobile app called MiDiálisis designed to help people on peritoneal dialysis (home dialysis) track their treatment. It looks at whether the app is easy to use and helpful for staying on track.
Madrid, MadridAges 18 years+ - NCT06885385RecruitingPhase 2
Study of JS207 with or without JS015 and chemo for colorectal cancer
This trial tests a new drug combination (JS207 with or without JS015) along with chemotherapy for people with advanced colorectal cancer that has not spread to other parts of the body. It aims to see if the treatment is safe and helps shrink tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT07327840RecruitingPhase 2
Study of Kylo-11 for heart disease with high Lp(a)
This trial tests a new drug, Kylo-11, for people with heart or blood vessel disease and high Lp(a), a type of cholesterol that raises risk of heart problems. The study will see if Kylo-11 can help lower that risk.
Los Angeles, CaliforniaAges 18–80 - NCT07681089RecruitingPhase 2
Foscenvivint for HIV/HCV cirrhosis with hemophilia
This trial tests a drug called foscenvivint for people with hemophilia and liver cirrhosis caused by both HIV and hepatitis C (already treated). The study aims to see if it can help improve liver health.
Sapporo, HokkaidoAges 18–79 - NCT07370207RecruitingPhase 2
Study of AHB-137 for HBeAg negative chronic hepatitis B
This study tests a new medicine called AHB-137 for people with chronic hepatitis B who are HBeAg negative and currently on antiviral therapy. The goal is to see if it can help control the virus better or allow you to stop your current medication safely.
Fitzroy, VictoriaAges 18–65 - NCT06419205RecruitingPhase 2
ADX-097 for IgA nephropathy, lupus nephritis, or C3G
This study tests an experimental oral therapy called ADX-097 for people with three types of kidney disease: IgA nephropathy, lupus nephritis, or C3 glomerulopathy. The goal is to see if it’s safe and can help reduce kidney damage.
Lawrenceville, GeorgiaAges 16 years+ - NCT07743112RecruitingPhase 2
Study of a new drug combo for untreated acute myeloid leukemia
This trial tests a new drug, MAX-40279, combined with two standard treatments (venetoclax and azacitidine) for people with newly diagnosed acute myeloid leukemia who are not healthy enough for intensive chemotherapy. The goal is to see if adding this drug improves outcomes.
TianjinAges 18 years+ - NCT07501702RecruitingPhase 2
Study of Povetacicept for Generalized Myasthenia Gravis
This trial tests a new medicine called povetacicept for people with generalized myasthenia gravis. The goal is to see if it can help improve muscle weakness and symptoms.
Mission Hills, CaliforniaAges 18–80 - NCT07005154RecruitingPhase 2
Study of ASP5541 for metastatic prostate cancer
This study tests an experimental drug called ASP5541 for men with metastatic prostate cancer (either hormone-sensitive or castration-resistant). It aims to see if the drug can slow cancer growth and improve outcomes when added to standard hormone therapy.
Huntsville, AlabamaAges 18 years+ - NCT07566364RecruitingPhase 2
Mosunetuzumab for Chronic Lymphocytic Leukemia with Minimal Residual Disease
This study tests a new antibody drug called mosunetuzumab in patients with chronic lymphocytic leukemia (CLL) who have already tried other treatments and still have detectable leukemia cells in their bone marrow. The drug is designed to work in a way that might help your immune system fight the remaining cancer cells.
Houston, TexasAges 18 years+ - NCT07535034RecruitingPhase 2
Testing Dotinurad for Gout in People Who Can't Take Other Medications
This trial tests a new drug called dotinurad for gout patients whose standard medications either don't work or cause side effects. Dotinurad works differently by helping your body get rid of uric acid (the substance that causes gout attacks), and the study will see if it safely lowers uric acid levels.
Granada Hills, CaliforniaAges 18–75 - NCT06563505RecruitingPhase 2
Study of mosunetuzumab plus zanubrutinib for relapsed marginal zone lymphoma
This trial tests a combination of two drugs (mosunetuzumab and zanubrutinib) for people with marginal zone lymphoma that has come back or stopped responding to prior treatment. The goal is to see if this combination can help control the lymphoma.
Houston, TexasAges 18 years+ - NCT06570798RecruitingPhase 2
Testing Two Drugs for Lupus and Rheumatoid Arthritis
This trial tests two study drugs, inebilizumab and blinatumomab, for people with lupus (SLE) or rheumatoid arthritis (RA) that hasn't gotten better with standard treatments. It focuses on those with active disease, especially lupus-related kidney problems.
Scottsdale, ArizonaAges 18–75 - NCT06968845RecruitingPhase 2
Study of LTI-03 for Idiopathic Pulmonary Fibrosis
This trial tests an inhaled drug called LTI-03 to see if it can help people with idiopathic pulmonary fibrosis (IPF). It may be an option for those with moderate lung function who are stable on their current treatment.
Birmingham, AlabamaAges 40 years+ - NCT07679893RecruitingPhase 2
Inhaled nintedanib for idiopathic pulmonary fibrosis
This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.
Windsor, OntarioAges 40–80 - NCT07482657RecruitingPhase 2
Zelicapavir for RSV in infants and toddlers
This trial tests a new medicine called Zelicapavir for babies and young children (28 days to 3 years old) who have respiratory syncytial virus (RSV) infection. The medicine aims to help them recover faster and with fewer complications.
BangkokAges 4 weeks–3 years
Hear when a new Phase 2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for phase 2?
- Yes. Clin2 currently lists 292 recruiting phase 2 studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a phase 2 trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a phase 2 trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.